司库奇尤单抗在中重度斑块状银屑病中的剂量优化:OPTIMISE随机开放标签研究结果
OPTIMISE研究纳入1647例中重度斑块状银屑病患者,先接受司库奇尤单抗300mg标准诱导后,第24周按PASI应答随机分组维持治疗至第52周。结论为300mg q4w是维持清除或几乎清除的最优方案;体重≥90kg且第24周未达PASI 90者可能从q2w获益。
要点
- 司库奇尤单抗300mg q4w是维持PASI 90的最优维持方案。
- PASI 90应答者中q6w维持PASI 90的比例低于q4w,非劣效未成立。
- 体重≥90kg且第24周未达PASI 90者,q2w可能获益。
核心结论
- 司库奇尤单抗300mg标准q4w给药是达到并维持皮损清除或几乎清除的最优剂量方案。
- 第24周未达PASI 90且体重≥90kg的患者,q2w给药可能获益。
研究设计与样本
- OPTIMISE为随机、开放标签、评分者盲的IIIb期研究。
- 共纳入1647例中重度斑块状银屑病患者,基线及第1、2、3、4周和第4周后每4周接受司库奇尤单抗300mg至第24周。
- 第24周PASI 90应答者(n=1306)随机接受300mg q4w(n=644)或q6w(n=662)至第52周。
- 第24周PASI≥75且<90应答者(n=206)随机接受300mg q4w(n=114)或q2w(n=92)至第52周。
主要发现
- q6w对比q4w的主要终点非劣效性未成立。
关键数值与推荐
- PASI 90应答定义为PASI改善≥90%。
临床怎么用
- 中重度斑块状银屑病维持治疗优选司库奇尤单抗300mg q4w。
- 对体重≥90kg且第24周未达PASI 90的患者,可考虑q2w强化给药。
- 不推荐将q6w作为常规维持方案替代q4w。
局限性
- 研究为开放标签设计,评分者盲法。
- q2w与q4w在PASI≥75且<90应答者及体重≥90kg亚组中的比较未达到统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralizes interleukin-17A. OBJECTIVES: To assess the efficacy and safety of different maintenance dosing regimens of secukinumab 300 mg based on Psoriasis Area and Severity Index (PASI) response at week 24 in patients with moderate-to-severe plaque psoriasis. METHODS: OPTIMISE was a randomized, open-label, rater-blinded phase IIIb study. Patients (n = 1647) received secukinumab 300 mg at baseline; weeks 1, 2, 3 and 4; and every 4 weeks (q4w) to week 24. At week 24, PASI 90 responders (≥ 90% improvement in PASI; n = 1306) were randomized to secukinumab 300 mg q4w (n = 644) or q6w (n = 662) to week 52, and PASI ≥ 75 to < 90 responders (n = 206) were randomized to secukinumab 300 mg q4w (n = 114) or q2w (n = 92) to week 52. RESULTS: PASI 90 response was maintained at week 52 by 85·7% of patients with q4w dosing vs. 74·9% with q6w dosing (odds ratio 1·91, 95% confidence interval 1·44-2·55). The primary end point, noninferiority of q6w vs. q4w dosing, was not met. In PASI ≥ 75 to < 90 responders, the proportion of patients with PASI 90 response at week 52 was numerically higher in the q2w vs. the q4w group (57% vs. 46·5%, respectively, P = 0·10). Heavier patients (≥ 90 kg) demonstrated numerically higher PASI 90 response with the q2w (57·1%) vs. the q4w regimen (40%, P = 0·11). CONCLUSIONS: Standard q4w dosing of secukinumab 300 mg is the optimal dosing regimen to achieve and maintain clear or almost clear skin. Patients with body weight ≥ 90 kg not achieving PASI 90 at week 24 may benefit from the q2w dosing regimen. What's already known about this topic? Individual responses to biologics in patients with psoriasis vary considerably and there may be a need to individualize treatment. Dose optimization strategies of currently available biologic drugs have been investigated mainly in rheumatic disorders. Secukinumab has shown long-term PASI 90/100 responses (percentage improvement in Psoriasis Area and Severity Index) to year 5 in patients with moderate-to-severe plaque psoriasis when used at the dose of 300 mg every 4 weeks. What does this study add? Standard every 4 week (q4w) dosing of secukinumab 300 mg is the optimal regimen to achieve and maintain clear or almost clear skin at week 52; the majority of the patients (85·7%) maintain PASI 90 at week 52. Superiority of intensified (q2w) dosing over the q4w regimen could not be claimed. However, patients with a higher body weight (≥ 90 kg) not achieving PASI 90 response at week 24 may benefit from q2w dosing.
引用
- Reich K, Puig L, Szepietowski JC, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2019. PMID: 31102257. doi:10.1111/bjd.18143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。